Martin Friedlander, MD, PhD

Insights shed light on what the approval means for providers and their patients affected by this neurodegenerative retinal disease

Martin Friedlander, MD, PhD, discusses phase 3 macular telangiectasia findings, highlighting the potential for a decade-long alternative to intravitreal injections.